Childhood Colitis Aggravates Gut Barrier Impairment Via MiR-196 When Exposed To Another Episode Of Inflammation In Adult-life | 93110
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background & Aims: Mounting evidence suggests that adverse early-life events influence the perinatal programming and
maturation of the immune system, predisposing the host to complex diseases including inflammatory bowel diseases (IBD).
We hypothesized that neonatal colonic inflammation generates long range epigenetic memory that aggravates epithelial barrier
impairment when exposed to another episode of inflammation in adult-life.
Methods: Neonatal inflammation (NI) was induced by intra rectal administration of trinitrobenzene sulfonic acid (TNBS, 130
mg/kg) on postnatal day 10. Another dose of TNBS (80 mg/kg) was applied to induce adult inflammation (AI) six weeks after
NI. All 4 groups of rats (Veh+Veh, NI+Veh, Veh+AI, and NI+AI) were euthanized 7 days later.
Results: In NI+AI rats, we observed an aggravated epithelial damage, evidenced by exacerbated increase in colonic permeability,
when compared with the other three groups of rats (p<0.01). We also tested the double-hit injury strategy in adult 6-week old
rats given 130 mg/kg TNBS. After 6 weeks of remission, another episode of adult inflammation was induced with TNBS (AI+AI
rats). There was no heightened tissue injury in AI+AI vs Veh+Veh, AI+Veh, and Veh+AI rats; noticeably less permeability was
detected when compared to the NI model. Thus, aberrant epithelial damage occurs preferentially after colonic injury in the
neonates. Molecular studies revealed a marginal decrease in Cdh1 mRNA and a significant reduction in E-cadherin protein
in the colon mucosa of NI+AI rats, while Occludin, ZO-1, Claudin 1, Claudin 5, and Claudin 7 remained unchanged. To
investigate the epigenetic mechanism underlying the loss of E-cadherin, we carried out miRNA arrays. miR-139, 196, 547,
and 3596 were significantly upregulated whereas Let-7e, miR-19a, 96 and 101a were markedly repressed in NI+AI vs the other
three groups of rats. Importantly, miR-196 is significantly elevated in patients with Crohn???s disease or colon cancer, indicating
a human clinical correlation. Bioinformatics analysis predicted E-cadherin, a key adhesion molecule involved in gut epithelial
integrity, as a target of miR-196. To determine its role in regulating E-cadherin, we overexpressed miR-196 in HT29 colorectal
cancer cells and found a significant decrease in E-cadherin mRNA and protein (p<0.01). Thus, we postulated that a miR-
196 inhibitor might decrease NI-induced disease susceptibility and might ameliorate epithelial barrier injury in NI+AI rats.
Intervention study with miR-196 inhibitor is currently ongoing.
Conclusions: Severe neonatal colonic inflammation renders the host susceptible to aggravated epithelial damage in part by
upregulating miR-196, which in turn downregulates E-cadherin, resulting in exacerbated increase in colonic permeability.
miR-196 could serve as a therapeutic target in IBD and colitis-associated colon cancer.
Qingjie Li, a Molecular Biologist, earned his MS Degree in Chemistry from the Department of Chemistry, Guangxi Normal University in 1991 and a PhD Degree in Biochemistry and Molecular Biology from the Central South University ( P R China) in 2000. He worked as a Faculty Member at the same university from 1991 to 2000 and as a Postdoctoral Fellow at the Linus Pauling Institute, Oregon State University from 2000 to 2006. In 2007, as an Assistant Professor he joined the University of Texas Medical Branch at Galveston. He was promoted to Associate Professor in 2018. He has several awards to his credit and has published more than 40 peer-reviewed research articles, a book chapter, and several gene sequences in GenBank. He has served as a Reviewer for NIH, American Gastroenterological Association, and numerous journals, including Gastroenterology, the most prominent journal in the field of gastrointestinal disease. His research interest include: pathogenesis, molecular mechanisms, and chemoprevention of inflammatory bowel diseases (IBD) and its comorbidities, including colitis-associated cancer and IBD-associated cardiovascular disorders.